2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception

Medicine & Life Sciences

• Neuroimaging 90%
• Alzheimer Disease 77%
• Biomarkers 37%
• Cerebrospinal Fluid 27%
• Amyloid 19%
• Positron-Emission Tomography 19%
• Cognitive Dysfunction 12%
• Magnetic Resonance Imaging 10%
• Sample Size 9%
• Alzheimer Disease 10 8%
• Health Care Outcome Assessment 6%
• Argentina 6%
• Fluorodeoxyglucose F18 5%
• Genome-Wide Association Study 5%
• Mental Status and Dementia Tests 5%
• Korea 5%
• Taiwan 5%
• Italy 4%
• Atrophy 4%
• Multicenter Studies 4%
• Longitudinal Studies 4%
• Japan 4%
• Molecular Biology 4%
• Early Diagnosis 4%
• China 4%
• Research Personnel 3%
• Elderly 3%
• Clinical Trials 3%
• Pathology 3%
• Costs and Cost Analysis 3%
• Phenotype 3%
• Brain 2%
• Pharmaceutical Preparations 2%

Social Sciences

• dementia 100%
• cognitive impairment 17%
• development of methods 11%
• embargo 5%
• Clinical Trials 4%
• pathology 4%
• Argentina 4%
• Korea 4%
• diagnostic 4%
• brain 3%
• Taiwan 3%
• Italy 3%
• longitudinal study 3%
• candidacy 3%
• Japan 3%
• rating 3%
• efficiency 3%
• infrastructure 3%
• drug 3%
• China 2%
• costs 2%